Controls nausea and vomiting associated with certain types of anesthesia and surgery. ANDA 40026, held by Chartwell Rx. Promethazine Hydrochloride.
As of Nov 16, 2026, ANDA 40026 (Promethazine Hydrochloride), held by Chartwell Rx, was first approved by FDA on Sep 25, 1998, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of postoperative pain.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 25, 1998 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Promethazine Hydrochloride6.25MG/5ML ยท syrup;oral | Promethazine Hydrochloride | Rx |
| Oct 7, 2009 | Supplement 9Labeling | Approved | None posted |
| Mar 22, 2007 | Supplement 6Labeling | Approved | None posted |
| Jun 12, 2006 | Supplement 5Labeling | Approved | None posted |
| Apr 3, 2006 | Supplement 4Labeling | Approved | None posted |
| Jul 27, 2005 | Supplement 3Labeling | Approved | None posted |
| Sep 25, 1998 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters